Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

With the reaffirmation of an earlier ruling from the U.S. Court of Appeals for the Federal Circuit, a major breakthrough took place for molecular diagnostic company Myriad Genetics, Inc. (MYGN - Analyst Report). The earlier ruling given on July 29, 2011 confirmed Myriad’s right to patent two isolated human genes - BRCA 1 and BRCA 2 - directly related to breast and ovarian cancer. However, the Supreme Court asked for a reconsideration of the whole matter.

The lawsuit was initiated on May 12, 2009 by the Association for Molecular Pathology, et al. (Plaintiffs) in the U.S. District Court for the Southern District of New York with the allegation that Myriad’s patents on BRCA 1 and BRCA 2 human genes were invalid and unlawful. Currently, Myriad has exclusive license rights to 525 claims in 24 issued U.S. patents related to Bracanalysis testing.

Bracanalysis is Myriad’s flagship product, contributing 81.7% of total revenue. This test provides a comprehensive analysis of BRCA 1 and BRCA 2 genes for assessing a woman's risk of hereditary breast and ovarian cancers. A woman testing positive for a deleterious mutation with the Bracanalysis test has an 82% risk of developing breast cancer and a 44% risk of developing ovarian cancer during her lifetime. The test is currently priced at $3,340.

However, the company noted that 95% of the U.S. patients requiring Bracanalysis can obtain coverage through private insurance, Medicare, Medicaid or Myriad's Financial Assistance Program. For the past 3 years, more than 5,000 patients have benefitted from this assistance program.

In the fourth quarter of 2012, revenues from Bracanalysis increased 17%. Foreseeing significant growth opportunity in the Women’s Health market for Bracanalysis, Myriad is currently focusing on penetrating the segments of ovarian cancer, carcinoma in situ and triple negative breast cancer indications.

We consider Myriad’s Bracanalysis system a valuable asset for top-line growth as it has the potential to tap a widely unexplored market. The company considers the oncology market to be huge, with Bracanalysis having penetrated about 50% of the cancer segment. As a result, the favourable second ruling by the U.S. federal appeals court may be considered a positive development for Myriad. The company is currently undertaking various strategies to increase both the market size and penetration level of Bracanalysis. During fiscal 2012, the company entered into agreements with Cephalon, a subsidiary of Teva Pharmaceutical (TEVA - Analyst Report) and Pharma Mar to conduct companion diagnostic testing for their clinical trials.

We currently have a Neutral recommendation on Myriad. The stock retains a Zacks #3 Rank (Hold in the short term).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%